Skip to main content
Yzen Al-Marrawi on Muck Rack

Yzen Al-Marrawi

As seen in: Frontiers
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yzen

Contact Yzen, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Ocular toxicities of targeted therapies and immunotherapies in hematologic malignancies

|
By Mohammad S. Aqil, Ahmad Abu-Mahfouz, Lavi Singh, Precious O. Idogun, Daniel Ezekwudo, Ishmael Jaiyesimi, Adam J. Weiner, Yzen Al-Marrawi, Marcus Yaldo, Swathi Gopishetty
| Frontiers
Background Targeted therapies and immunotherapies have revolutionized the treatment of hematologic malignancies over the past 15 years. Chimeric antigen receptor T-cell (CAR T-cell) therapies, tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), and other novel agents (e.g. bispecific antibodies, monoclonal antibodies, antibody-drug conjugates, and small-molecule inhibitors) have greatly improved outcomes in leukemias, lymphomas, and myeloma (1, 2).
Open in Who Shared Issue with article?
See all 1 articles